Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 7/20 | 0.74 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.68 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.68 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.68 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.68 |
| ▸ | F2 | P00734 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.66 |
| ▸ | PKM | P14618 | 3/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | ABL1 | P00519 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | IDE | P14735 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30569618 | 1.00 | FOLH1 (0.74) | FOLH1PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL29358108 | 1.00 | FOLH1 (0.74) | FOLH1PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL31248175 | 1.00 | FOLH1 (0.74) | FOLH1PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL15279176 | 1.00 | FOLH1 (0.74) | FOLH1PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL17975148 | 1.00 | FOLH1 (0.74) | FOLH1PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL18690250 | 1.00 | FOLH1 (0.74) | FOLH1PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL31510306 | 1.00 | FOLH1 (0.74) | FOLH1PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL17841934 | 1.00 | FOLH1 (0.74) | FOLH1PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL13907093 | 1.00 | FOLH1 (0.74) | FOLH1PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL30689887 | 1.00 | FOLH1 (0.74) | FOLH1PRSS1PRSS2PRSS3TPSAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713340-A2 | COMPOSITIONS AND METHODS FOR PEPTIDE-BASED MODULATORS OF HUMAN PAPILLOMAVIRUS ONCOPROTEIN E6 | Calico Life Sciences LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20250270162-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | LIGHTHOUSE PHARMACEUTICALS, INC. (US) | 2025-08-28 | — | — | US | disclosed |
| WO-2025151487-A2 | SMALL-MOLECULE INHIBITORS OF ADAR1 | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2025-07-17 | — | — | WO | disclosed |
| WO-2025111511-A2 | REVERSIBLY REACTIVE AFFINITY SELECTION MASS SPECTROMETRY AND USES THEREOF | CALICO LIFE SCIENCES LLC (US) | 2025-05-30 | — | — | WO | disclosed |
| EP-4480541-A2 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Lighthouse Pharmaceuticals, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| US-12110263-B2 | Ketone inhibitors of lysine gingipain | LIGHTHOUSE PHARMACEUTICALS, INC. (US) | 2024-10-08 | — | — | US | disclosed |
| US-20240279201-A1 | DUAL WNT SIGNALING PATHWAY INHIBITORS AND AMPK ACTIVATORS FOR TREATMENTS OF DISEASE | UNIVERSITY OF MARYLAND, BALTIMORE | 2024-08-22 | — | — | US | disclosed |
| EP-3512846-B1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | LIGHTHOUSE PHARMACEUTICALS INC (US) | 2024-08-14 | — | — | EP | disclosed |
| WO-2024124156-A1 | N-HETEROCYCLIC CARBENE MONOLAYERS AS ANALYTICAL REPORTERS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2024-06-13 | — | — | WO | disclosed |
| EP-4346811-A1 | DUAL WNT SIGNALING PATHWAY INHIBITORS AND AMPK ACTIVATORS FOR TREATMENTS OF DISEASE | University of Maryland, Baltimore (US) | 2024-04-10 | — | — | EP | disclosed |
| WO-2016077378-A1 | SUBSTITUTED PYRROLOPYRDINES AS INHIBITORS OF BROMODOMAIN | GENENTECH, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
| WO-2016077375-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
| US-20140315884-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2014-10-23 | — | — | US | disclosed |
| US-8791136-B2 | Substituted pyridine, pyridazine, pyrazine and pyrimidine compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20130203987-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| EP-2598483-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | Rigel Pharmaceuticals, Inc. (US) | 2013-06-05 | — | — | EP | disclosed |
| US-8198020-B2 | Contacting target cell or noncellular molecular entity with phagocytic marker and moiety that binds to a component that is present on or at surface of target cell or noncellular molecular entity, thereby increasing level or density of phagocytic marker on target cell; marker comprises phosphatidylserine | POTENTIA PHARMACEUTICALS, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20120028954-A1 | Substituted Pyridine, Pyridazine, Pyrazine And Pyrimidine Compounds And Methods For Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2012016217-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | WO | disclosed |
| US-20050113297-A1 | Compositions and methods for enhancing phagocytosis or phagocyte activity | POTENTIA PHARMACEUTICALS, INC. | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12110263-B2 | Ketone inhibitors of lysine gingipain | PHYKPL, ENPEP, PREP | FOLH1 280/4885PRSS1 140/4885PRSS2 389/4885 |
| US-20120028954-A1 | Substituted Pyridine, Pyridazine, Pyrazine And Pyrimidine Compounds And Methods For Using The Same | AK2, PC, PRKAG2 | FOLH1 3462/4885PRSS1 3397/4885PRSS2 3665/4885 |
| US-20050113297-A1 | Compositions and methods for enhancing phagocytosis or phagocyte activity | CD47, ANXA11, ANXA1 | FOLH1 611/4885PRSS1 382/4885PRSS2 1004/4885 |
| US-20140315884-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | PRKAG1, PRKAG2, PRKAB1 | FOLH1 3645/4885PRSS1 4369/4885PRSS2 4492/4885 |
| US-20250270162-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | PHYKPL, ENPEP, PREP | FOLH1 280/4885PRSS1 140/4885PRSS2 389/4885 |
| US-20130203987-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | PRKAG1, PRKAG2, PRKAB1 | FOLH1 3645/4885PRSS1 4369/4885PRSS2 4492/4885 |
| US-20240279201-A1 | DUAL WNT SIGNALING PATHWAY INHIBITORS AND AMPK ACTIVATORS FOR TREATMENTS OF DISEASE | PRKAB2, PRKAB1, PRKAG2 | FOLH1 2503/4885PRSS1 3972/4885PRSS2 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.